A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension

Funding

MHO reports grants from Centers for Disease Control and Prevention, during the conduct of the study, and personal fees from Boehringer Ingelheim, outside the submitted work. PB reports grants from Servier, and grants and personal fees from Withings, during the conduct of the study. JAC reports grants and personal fees from BMS, Fukuda Denshi, and Microsoft Research, and personal fees from OPKO Healthcare, Vital Labs, and Merck, during the conduct of the study. JAC is named inventor in a patent application (pending) for the use of inorganic nitrate and nitrite in heart failure and preserved ejection fraction. VP reports grants from Abbvie, Astellas, Bayer, Baxter, GSK, Bristol-Myers Squibb Company, Eli Lilly, Servier, Pfizer, and the National Health and Medical Research Council; personal fees from Servier; other support from Janssen, Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Pharmalink, and Relypsa, outside the submitted work. ERR reports grants from Amgen, Sanofi, and Unilever, outside the submitted work. GS reports grants from AtCor Medical, and personal fees from Fukuda-Denshi, Servier, Daiichi-Sankyo, Menarini, Novartis, and Guidotti, outside the submitted work. JES has received equipment and support in kind for research projects related to blood pressure from AtCor Medical and IEM GmbH. JGW reports personal fees from Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi, and Servier, outside the submitted work. All other authors declare no competing interests. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.